These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 14720012)

  • 21. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
    Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
    Barst RJ; Rubin LJ; McGoon MD; Caldwell EJ; Long WA; Levy PS
    Ann Intern Med; 1994 Sep; 121(6):409-15. PubMed ID: 8053614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
    Gomberg-Maitland M; Olschewski H
    Eur Respir J; 2008 Apr; 31(4):891-901. PubMed ID: 18378784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled treprostinil: a therapeutic review.
    Channick RN; Voswinckel R; Rubin LJ
    Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experiences with treprostinil in the treatment of pulmonary arterial hypertension.
    Stream AR; Bull TM
    Ther Adv Respir Dis; 2012 Oct; 6(5):269-76. PubMed ID: 22868690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin and pulmonary arterial hypertension.
    Braun-Moscovici Y; Nahir AM; Balbir-Gurman A
    Semin Arthritis Rheum; 2004 Aug; 34(1):442-53. PubMed ID: 15305243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.
    Walkey AJ; Fein D; Horbowicz KJ; Farber HW
    Pulm Pharmacol Ther; 2011 Aug; 24(4):421-5. PubMed ID: 21251994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
    Olschewski H; Walmrath D; Schermuly R; Ghofrani A; Grimminger F; Seeger W
    Ann Intern Med; 1996 May; 124(9):820-4. PubMed ID: 8610951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
    Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
    J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension.
    Galiè N; Manes A; Branzi A
    Eur Respir J; 2002 Oct; 20(4):1037-49. PubMed ID: 12412701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension.
    Mubarak KK
    Respir Med; 2010 Jan; 104(1):9-21. PubMed ID: 19683911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pulmonary hypertension and right ventricular failure. Part X. Prostanoids in the treatment of primary pulmonary arterial hypertension].
    Batyraliev TA; Makhmutkhodzhaev SA; Ekinci E; Pataraia SA; Pershukov IV; Sidorenko BA; Preobrazhenskiĭ DV
    Kardiologiia; 2007; 47(6):70-7. PubMed ID: 18260882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical therapy of pulmonary hypertension. The prostacyclins.
    Galié N; Manes A; Branzi A
    Clin Chest Med; 2001 Sep; 22(3):529-37, x. PubMed ID: 11590846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhaled treprostinil and pulmonary arterial hypertension.
    Nadler ST; Edelman JD
    Vasc Health Risk Manag; 2010 Dec; 6():1115-24. PubMed ID: 21191432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.